Neuspera Medical announced today that the Centers for Medicare & Medicaid Services (CMS) confirmed its SNM system’s billing code.
CMS assigned the Neurspera SNM (sacral neuromodulation) system to payment level APC 5464 in the proposed CY 2027 Outpatient Prospective Payment System Rule. This provides the externally powered integrated SNM (iSNM) system the same Medicare payment as all other implantable neuromodulation therapies for urinary urge incontinence (UUI). It also increases the payment rate for APC 5464 to $22,150 for CY 2027, marking an 11.8% increase from 2026.
San Jose, California-based Neuspera says the updated coding provides broad, straightforward access for Medicare beneficiaries.
Neuspera SNM holds FDA approval for the treatment of UUI, having earned the nod about a year ago. The discreet, non-invasive device also received FDA clearance in 2024 for the treatment of chronic pain of peripheral nerve origin.
The iSNM system offers the capabilities of existing SNM but in an advanced form factor. Patients receive a smart, miniaturized neurostimulator implant near the sacral nerve. They activate therapy using an external disc worn against the lower back for approximately two hours daily.
When not in use, the therapy disc charges wirelessly, like a smartphone. The intelligent system supports complex neuromodulation therapy delivery while eliminating the complications related to implanted batteries. According to Neuspera, it addresses common patient concerns without compromising performance. The system offers an alternative to fully implantable SNM systems like those from Axonics (now part of Boston Scientific) and Medtronic, among others.
David Van Meter, Neuspera CEO, said in a news release:
“We commend CMS for their thorough review and for making the decision to assign APC Level 4 to the Neuspera sacral neuromodulation system, with a strong proposed payment increase. This puts us on equal footing and will allow many more patients to benefit from SNM without the complications of implanted batteries commonly associated with legacy systems. A testament to the importance of our therapy is the opposition it faced from those invested in the status quo.2,3 Ultimately, what is best for patients prevailed.”
